Retatrutide
Under ReviewOverview
Retatrutide is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It is not yet TGA-approved and remains in Phase 3 clinical trials globally. Grey market supply has emerged in Australia.
Australian Scheduling
Schedule 4 (Prescription Only). Not yet TGA-approved or ARTG-listed. Under active regulatory monitoring. Grey market supply is under increasing scrutiny.
Access Pathway
Very limited legal prescription access through 2 identified providers. Most Australian supply is currently through grey market channels, which carries significant regulatory and quality risk.
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.